Abstract:Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit their benefits. Metabolic reprogramming appears to be one of the crucial barriers to immunotherapy. The deprivation of required nutrients and altered metabolites not only promote tumor progression but also confer dysfunction on immune cells in the tumor microenvironment (TME). Glycolysis plays a central role in metabolic reprogramming and immunoregulation in the TME, and many therapies targeting glycolysis have been developed, and their combinations with ICIs are in preclinical and clinical trials. Additional attention has been paid to the role of amino acids, lipids, nucleotides and mitochondrial biogenesis in metabolic reprogramming and clinical anti-tumor therapy. This review attempts to describe reprogramming metabolisms within tumor cells and immune cells, from the aspects of glycolysis, amino acid metabolism, lipid metabolism, nucleotide metabolism and mitochondrial biogenesis and their impact on immunity in the TME, as well as the significance of targeting metabolism in anti-tumor therapy, especially in combination with ICIs. In particular, we highlight the expression mechanism of programmed cell death (ligand) 1 [PD-(L)1] in tumor cells and immune cells under reprogramming metabolism, and discuss in detail the potential of targeting key metabolic pathways to break resistance and improve the efficacy of ICIs based on results from current preclinical and clinical trials. Besides, we draw out biomarkers of potential predictive value in ICIs treatment from a metabolic perspective.

Metabolic Implications of Immune Checkpoint Proteins in Cancer

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Data from Interplay Between Immune Checkpoint Proteins and Cellular Metabolism

Tumor Immune Checkpoints and Their Associated Inhibitors

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment

Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy

Metabolic Checkpoints and Novel Approaches for Immunotherapy Against Cancer

Metabolic Interventions Combined with CTLA-4 and PD-1/PD-L1 Blockade for the Treatment of Tumors: Mechanisms and Strategies.

Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance

The interplay between metabolic adaptations and diet in cancer immunotherapy

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota

Metabolic Crosstalk in the Tumor Microenvironment Regulates Antitumor Immunosuppression and Immunotherapy Resisitance.

Changes in tumor and cardiac metabolism upon immune checkpoint

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

Altered cancer metabolism in mechanisms of immunotherapy resistance

Immunometabolism: a new dimension in immunotherapy resistance

Metabolic rewiring and communication in cancer immunity

Metabolic Modifications, Inflammation, and Cancer Immunotherapy